Why the study?
The mechanisms behind the beneficial actions of finerenone and semaglutide in heart failure with preserved ejection fraction remain enigmatic, and prior trials of aldosterone blockade were limited by side effects.
RCT (n=66)
Double-blind
Randomly assigned
No
Answers are grounded in this paper and cite their sources.
This review highlights the need to understand the mechanisms behind the beneficial actions of finerenone and semaglutide in heart failure.
Obesity and type 2 diabetes mellitus commonly coexist with heart failure (HF) and may contribute to the pathogenesis of HF with preserved ejection fraction. With progression in management therapies for HF with preserved ejection fraction, the mechanism behind beneficial actions of finerenone and semaglutide remains enigmatic. For decades, the cardiorenal protective effects of aldosterone blockage in patients with chronic kidney disease have been of significant interest. But due to multiple side effects, these trials were likely to stop.
No takes yet. Share an insight, caveat, or question.
Muhammad Abdul Rehman Gulzar (2025) conducted an RCT in Type 2 diabetes and left ventricular hypertrophy (n=66). Dapagliflozin vs. Placebo was evaluated on Change in absolute left ventricular mass (LVM) (MD -2.82, 95% CI -5.13 to -0.51, p=0.018).
Synapse has enriched 10 related papers. Consider them for comparative context: